PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q96012

Kiyotaka KUZUSHIMA

Appln. No.: 10/586,852

Group Art Unit: Unassigned

Confirmation No.: 1872

Examiner: Unassigned

Filed: July 20, 2006

For:

EPITOPE/PEPTIDE RECOGNIZED BY HLA-A2402-RESTRICTED EP/CAM-

SPECIFIC CTL AND USE OF THE SAME

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, along with a copy of the corresponding Communication from a Foreign Patent Office, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action

Attorney Docket No.: Q96012

INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: 10/586,852

on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required. However, since a statement can be made, a statement is submitted herewith, together with a copy of a corresponding Communication from a Foreign Patent Office.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The following references were cited in the July 20, 2006 Information Disclosure Statement: WO/9715597, WO/03012086, JP/11318455, JP/2002510496, JP/2003533175, JP/2003510334, JP/2000116383, JP/2001245675 and Non Patent Document by K.C. Parker et al., "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptides Side-Chains", Journal of. Immunology. (1974), Vol. 152, pages 163-175.

The following references were cited in the September 19, 2006 Information Disclosure Statement: US/6664232, WO/0006595, WO/9403435, WO/0136453, WO/0123421 CA/0325345, JP/2003270, JP/8500103; Non Patent Document by K. Tajima et al., "Identification of an Epitope for the Epithelial Cell Adhesion Molecule Eliciting HLA-A*2402-Restricted Cytotoxic T-Lymphocyte Responses", Tissue Antigens (2004),Vol. 64, pages 650-659 and Non Patent Document by G.V. Ullenberg et al., "Immunization of Colorectal Carcinoma Patients with a Recombinant Canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte Macrophage Colony-Stimulating Factor Induced a Tumor-

INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: 10/586,852

Attorney Docket No.: Q96012

Specific Cellular Immune Response", Clinic of Cancer Research, (2003), Vol. 9, pages 2447-

2456.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The U.S.P.T.O. is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 30,764

Gordon Kit

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: March 6, 2008

3

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q96012

Kiyotaka KUZUSHIMA

Appln. No.: 10/586,852

Group Art Unit: Unassigned

Confirmation No.: 1872

Examiner: Unassigned

Filed: July 20, 2006

For: EPITOPE/PEPTIDE RECOGNIZED BY HLA-A2402-RESTRICTED EP/CAM-

SPECIFIC CTL AND USE OF THE SAME

STATEMENT UNDER 37 CFR § 1.97(e)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The undersigned hereby states, upon information and belief:

That each item of information contained in the Information Disclosure Statement filed concurrently herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of said Information Disclosure Statement.

Respectfully submitted,

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

washington office 23373
customer number

Date: March 6, 2008

Gordon Kit

Registration No. 30,764